Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

clarkhealthcommunications

- PMLiVE

Roche announces FDA approval of self-collection solution for HPV screening

More than 13,000 people are diagnosed with cervical cancer every year in the US

- PMLiVE

Trial reveals promising results for radiotherapy/hormone therapy combination in prostate cancer

Further evidence is being sought from the phase 2 TRAP trial results through the larger STAR-SHIP study

- PMLiVE

Pioneering Paths: Women Leadership in Rare Disease

Rare diseases are often thought of as affecting one in 100,000 or one in 1,000,000 people, and that is true for some conditions. But there are many rare diseases that...

Medscape Education Global

- PMLiVE

Takeda gains exclusive option for AC Immune’s Alzheimer’s drug candidate in deal worth over $2.1bn

The agreement includes an option to licence global rights to the anti-amyloid beta immunotherapy

- PMLiVE

Sanofi, Pfizer and AstraZeneca commit €2.5bn investment to biomanufacturing projects in France

The investments are part of the wider €15bn investment for the Choose France event

- PMLiVE

Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study

Haemophilia A accounts for up to 85% of the 1,125,000 global haemophilia cases

- PMLiVE

WHO opens application period for 2025 Model Lists of Essential Medicines

The deadline to submit ahead of the 25th WHO Expert Committee meeting is 1 November 2024

- PMLiVE

Pfizer’s Vyndaqel recommended by NICE to treat rare heart disease ATTR-CM

Approximately 1,500 people in England are affected by transthyretin amyloidosis cardiomyopathy

- PMLiVE

PharmaTimes Medical & Scientific Excellence Awards and Nursing Industry Excellence Awards open for entry

Both awards are open for entry until 17 May 2024 and the live awards ceremony will take place on 11 July 2024

- PMLiVE

Valneva’s single-dose chikungunya vaccine shows promise in adolescents

The mosquito-borne viral disease often causes sudden, large outbreaks with high attack rates

- PMLiVE

NICE recommends three tumour profiling tests for early breast cancer patients

Breast cancer is the most common cancer in the UK, affecting more than 55,000 people every year

- PMLiVE

Study reveals third COVID-19 vaccine dose improves defence in vulnerable patients

Approximately 90% of patients who received a third dose developed significant levels of antibodies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links